Redeye updates its estimates and valuation following MedCap’s Q2 2025 report.
Redeye comments on Polygiene Group´s Q2 2025. Polygiene Group delivered negative growth of -12% y/y.
Sales and EBIT miss of SEK 22m and 7m vs. ABGSCe This afternoon, Energy Save issued a profit warning...
Physitrack’s Q2 2025 results came in broadly in line with our expectations.
Redeye shares its initial view on Modelon’s Q2 2025 report.
Prisma redovisade en stark Q2 med 15,5 % högre intäkter och ett förvaltningsresultat på 48 Mkr (11).
Hanza levererade ett starkt Q2 med 3 % organisk tillväxt och rörelseresultat på 97 Mkr, i linje med ...
Redeye returns with a more in-depth take on the Q2 report.
Bright spot in FMWT Q2 sales were SEK 228m, -3% y-o-y and flat y-o-y in local currencies, while EBIT...
Q2 yet another miss As feared, Invisio faced tough comps in Q2 and missed expectations across most k...
Q2 results Sales fell 3% y-o-y and were 7% below our estimate.
Redeye leaves an initial comment on the strong Q2 report, where OPEX cuts and higher distributor sal...
Redeye comments on the takeover bid from OsteoCentric.
Redeye provides a brief comment on FMG’s downward revision of its full-year guidance.
OEM challenges delay ramp-up, again CTT continues to suffer from supply chain challenges at its cust...
Studentbostäder i Norden rapporterar ett andra kvartal i linje med våra förväntningar påverkat av sä...
Q2 expectations We expect Q2 sales of EUR 43m, +1% y-o-y and +11% q-o-q.
Redeye is encouraged by FluoGuide announcing a non-exclusive collaboration with global medtech compa...
Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, whil...
Order backlog at its highest level since Q2/23 Consti’s steady development continued during the se...
